Supreme Court Upholds , FDA Regulation on Popular , Abortion Drug Mifepristone.br On June 13, the Supreme Court ruled against a group of br doctors who challenged the Food and Drug Administration's br (FDA) regulations on the abortion pill mifepristone.br CBS reports that the case once again highlighted br abortion access following the conservative br majority decision to overturn Roe v. Wade in 2022.br The court ruled unanimously that the group of br anti-abortion rights doctors and medical associations br lacked the legal right to challenge the FDA. .br However, the court also did not address br whether the FDA's decision to relax the br rules for mifepristone's use were lawful. .br The latest ruling was authored br by Justice Brett Kavanaugh. .br Under Article III of the Constitution, br a plaintiff's desire to make a drug br less available for others does br not establish standing to sue. , Justice Brett Kavanaugh writing for the court, via CBS.br Nor do the plaintiffs' other br standing theories suffice. br Therefore, the plaintiffs lack br standing to challenge FDA's actions, Justice Brett Kavanaugh writing for the court, via CBS.br CBS reports that the ruling does not impact other br challenges to the FDA's standing on mifepristone, br while preserving access to the popular abortion medication.br In 2016 and 2021, the FDA took steps to widen access br to mifepristone, which has been taken by over br 5 million patients since first being approved in 2000.br Those steps included allowing the drug to be taken up to 10 br weeks into a pregnancy, reducing the number of in-person br doctor visits and permitting it to be sold through the mail.